8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 1, 2026·SEC
Material company update
Mar 9, 2026·SEC
Design Therapeutics, Inc.(DSGN)Earnings, Financials & Key Ratios
DSGN•NASDAQ
Price updated Jun 19, 2026
AboutDesign Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Show more
- Revenue$0
- EBITDA-$79M-27.6%
- Net Income-$70M-40.7%
- EPS (Diluted)-1.22-38.6%
- ROE-30.7%-60.9%
DSGN Key Insights
Design Therapeutics, Inc. (DSGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 83 (top 17%)
✗Weaknesses
- ✗Profits declining 53.2% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DSGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DSGN Price & Volume
Design Therapeutics, Inc. (DSGN) stock price & volume — 10-year historical chart
Loading chart...
DSGN Growth Metrics
Design Therapeutics, Inc. (DSGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-24.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-21.21%
Return on Capital
10 Years-29.37%
5 Years-24.04%
3 Years-28.08%
Last Year-34.79%
DSGN Recent Earnings
Design Therapeutics, Inc. (DSGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$0.29+19.4%
$0.36
Rev
—
—
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.27+28.9%
$0.38
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.30+11.8%
$0.34
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.34-6.3%
$0.32
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.29vs $0.36+19.4% | — |
| Q2 2026 | Mar 9, 2026 | $0.27vs $0.38+28.9% | — |
| Q4 2025 | Nov 5, 2025 | $0.30vs $0.34+11.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.34vs $0.32-6.3% | — |
Based on last 12 quarters of dataView full earnings history →
DSGN Peer Comparison
Design Therapeutics, Inc. (DSGN) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FULC | 200.21M | 3.70 | -3.14 | -100% | -27.8% | 0.02 | ||
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare DSGN vs Peers
Design Therapeutics, Inc. (DSGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DSGN Income Statement
Design Therapeutics, Inc. (DSGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 834 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | -100% | - | - | - | - | - | - |
Cost of Goods Sold | 1.65K | 5K | 0 | 466K | 537K | 596K | 622K | 0 |
COGS % of Revenue | 198.32% | - | - | - | - | - | - | - |
Gross Profit | -820▲ 0% | -5K▼ 509.8% | 0▲ 100.0% | -466K▲ 0% | -537K▼ 15.2% | -596K▼ 11.0% | -622K▼ 4.4% | 0▲ 0% |
Gross Margin % | -98.32% | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -509.76% | 100% | - | -15.24% | -10.99% | -4.36% | - |
Operating Expenses | 1.91M | 8.55M | 35.83M | 67.13M | 77.65M | 61.79M | 78.84M | 78.75M |
OpEx % of Revenue | 228776.98% | - | - | - | - | - | - | - |
Selling, General & Admin | 1.09M | 2.5M | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M | 20.62M |
SG&A % of Revenue | 130455.64% | - | - | - | - | - | - | - |
Research & Development | 1.65M | 6.06M | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M | 58.13M |
R&D % of Revenue | 198321.34% | - | - | - | - | - | - | - |
Other Operating Expenses | -834K | 0 | 0 | -466K | -537K | -596K | -622K | -152K |
Operating Income | -1.91M▲ 0% | -8.56M▼ 348.4% | -35.83M▼ 318.8% | -67.59M▼ 88.6% | -78.19M▼ 15.7% | -62.38M▲ 20.2% | -79.47M▼ 27.4% | -78.75M▲ 0% |
Operating Margin % | -228776.98% | - | - | - | - | - | - | - |
Operating Income Growth % | - | -348.43% | -318.78% | -88.64% | -15.68% | 20.22% | -27.39% | - |
EBITDA | 0 | -8.55M | -35.7M | -67.13M | -77.65M | -61.79M | -78.84M | -78.29M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | -317.52% | -88.02% | -15.68% | 20.43% | -27.61% | -15.49% |
D&A (Non-Cash Add-back) | 1.91M | 5K | 129K | 466K | 537K | 596K | 622K | 463K |
EBIT | -2.05M | -8.28M | -35.83M | -63.31M | -66.86M | -49.59M | -79.47M | -54.25M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 12.79M | 9.68M | 6.97M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 12.79M | 9.68M | 9.04M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -139K | 276K | 298K | 4.29M | 11.33M | 12.79M | 9.68M | 9.04M |
Pretax Income | -2.05M▲ 0% | -8.28M▼ 304.5% | -35.53M▼ 329.1% | -63.31M▼ 78.2% | -66.86M▼ 5.6% | -49.59M▲ 25.8% | -69.79M▼ 40.7% | -69.71M▲ 0% |
Pretax Margin % | -245443.65% | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.05M▲ 0% | -8.28M▼ 304.5% | -35.53M▼ 329.1% | -63.31M▼ 78.2% | -66.86M▼ 5.6% | -49.59M▲ 25.8% | -69.79M▼ 40.7% | -69.71M▲ 0% |
Net Margin % | -245443.65% | - | - | - | - | - | - | - |
Net Income Growth % | - | -304.49% | -329.14% | -78.17% | -5.61% | 25.84% | -40.74% | -24.05% |
Net Income (Continuing) | -2.05M | -8.28M | -35.53M | -63.31M | -66.86M | -49.59M | -69.79M | -69.71M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.08▲ 0% | -0.30▼ 298.4% | -0.77▼ 156.7% | -1.14▼ 48.1% | -1.19▼ 4.4% | -0.88▲ 26.1% | -1.22▼ 38.6% | -1.13▲ 0% |
EPS Growth % | - | -298.41% | -156.67% | -48.05% | -4.39% | 26.05% | -38.64% | -21.21% |
EPS (Basic) | -0.08 | -0.30 | -0.77 | -1.14 | -1.19 | -0.88 | -1.22 | - |
Diluted Shares Outstanding | 27.19M | 27.19M | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M | 61.43M |
Basic Shares Outstanding | 27.19M | 27.19M | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M | 61.43M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
DSGN Balance Sheet
Design Therapeutics, Inc. (DSGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 90K | 36.23M | 385.44M | 335.12M | 284.58M | 248.04M | 223.78M | 227.05M |
Cash & Short-Term Investments | 77K | 36.09M | 384.06M | 330.39M | 281.8M | 245.48M | 219.84M | 222.82M |
Cash Only | 77K | 2.38M | 298.57M | 26.5M | 21.2M | 22.56M | 16.86M | 12.77M |
Short-Term Investments | 0 | 33.71M | 85.5M | 303.89M | 260.6M | 222.91M | 202.99M | 210.05M |
Accounts Receivable | 0 | 10K | 110K | 1.11M | 1.43M | 1.26M | 1.68M | 1.82M |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 8K | 25K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 0 | 283K | 5.12M | 6.02M | 5.06M | 4.05M | 2.42M | 3.39M |
Property, Plant & Equipment | 0 | 71K | 5.12M | 5.56M | 4.63M | 3.63M | 2.42M | 3.39M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 212K | 0 | 459K | 430K | 427K | 0 | 0 |
Total Assets | 90K▲ 0% | 36.52M▲ 40473.3% | 390.56M▲ 969.6% | 341.14M▼ 12.7% | 289.64M▼ 15.1% | 252.09M▼ 13.0% | 226.2M▼ 10.3% | 230.44M▲ 0% |
Asset Turnover | 0.01x | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 40473.33% | 969.55% | -12.65% | -15.09% | -12.96% | -10.27% | -49.61% |
Total Current Liabilities | 3.73M | 2.33M | 5.28M | 10.78M | 9.62M | 8.46M | 13.05M | 10.19M |
Accounts Payable | 2.48M | 1.4M | 1.62M | 3.02M | 1.94M | 2.19M | 2.31M | 2.28M |
Days Payables Outstanding | 547.06K | 102.13K | - | 2.37K | 1.32K | 1.34K | 1.36K | - |
Short-Term Debt | 695K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 201K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 112K | 565K | 2.15M | 3.54M | 4.03M | 0 | 10.74M | 2.33M |
Current Ratio | 0.02x | 15.55x | 72.96x | 31.10x | 29.58x | 29.31x | 17.14x | 22.28x |
Quick Ratio | 0.02x | 15.55x | 72.96x | 31.10x | 29.58x | 29.31x | 17.14x | 22.28x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 1K | 45.5M | 3.14M | 3.05M | 2.33M | 1.53M | 645K | 2.2M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 645K | 0 |
Capital Lease Obligations | 0 | 0 | 3.14M | 3.05M | 2.33M | 1.53M | 0 | 4.82M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1K | 45.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.73M | 47.83M | 8.43M | 13.83M | 11.96M | 10M | 13.7M | 12.39M |
Total Debt | 695K | 0 | 3.63M | 3.69M | 3.05M | 2.33M | 645K | 2.73M |
Net Debt | 618K | -2.38M | -294.94M | -22.81M | -18.15M | -20.23M | -16.21M | -10.04M |
Debt / Equity | - | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.13x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | -3.64M▲ 0% | -11.31M▼ 210.7% | 382.13M▲ 3477.2% | 327.31M▼ 14.3% | 277.69M▼ 15.2% | 242.1M▼ 12.8% | 212.5M▼ 12.2% | 218.05M▲ 0% |
Equity Growth % | - | -210.68% | 3477.2% | -14.35% | -15.16% | -12.82% | -12.22% | -55.89% |
Book Value per Share | -0.13 | -0.42 | 8.32 | 5.88 | 4.96 | 4.28 | 3.71 | 3.55 |
Total Shareholders' Equity | -3.64M | -11.31M | 382.13M | 327.31M | 277.69M | 242.1M | 212.5M | 218.05M |
Common Stock | 1K | 1K | 6K | 6K | 6K | 6K | 6K | 6K |
Retained Earnings | -3.64M | -11.92M | -47.46M | -110.76M | -177.63M | -227.21M | -297.01M | -314.64M |
Treasury Stock | 0 | -451K | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 156K | -244K | -3.36M | 62K | 475K | 403K | -268K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DSGN Cash Flow Statement
Design Therapeutics, Inc. (DSGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -139K | -8.67M | -29.38M | -51.32M | -58.56M | -43.1M | -54.36M | -54M |
Operating CF Margin % | -16666.67% | - | - | - | - | - | - | - |
Operating CF Growth % | - | -6136.69% | -238.87% | -74.68% | -14.11% | 26.39% | -26.11% | -64.41% |
Net Income | -2.05M | -8.28M | -35.53M | -63.31M | -66.86M | -49.59M | -69.79M | -69.71M |
Depreciation & Amortization | 0 | 5K | 129K | 406K | 537K | 596K | -2.63M | 1.02M |
Stock-Based Compensation | 0 | 450K | 4.69M | 10.93M | 13.09M | 13.07M | 14.55M | 14.93M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 95K | -33K | -58K | -1.33M | -6.05M | -6.19M | 406K | -5.06M |
Working Capital Changes | 1.81M | -811K | 1.4M | 1.99M | 728K | -993K | 3.11M | 4.82M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | -413K | 2.41M | 5.38M | -1.25M | -1.22M | 4.49M | 2.28M |
Cash from Investing | 0 | -33.56M | -53.64M | -220.99M | 52.54M | 43.95M | 22.91M | 7.45M |
Capital Expenditures | 0 | -76K | -1.54M | -918K | -256K | -340K | -193K | -121K |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 52.11K | 39K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -52.11K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 196K | 44.53M | 379.21M | 235K | 724K | 513K | 25.74M | 45.65M |
Debt Issued (Net) | 196K | -200K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 44.73M | 378.98M | 662K | 724K | 513K | 25.74M | 25.71M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 1K | 228K | -427K | 0 | 0 | 0 | 19.93M |
Net Change in Cash | 57K▲ 0% | 2.3M▲ 3938.6% | 296.19M▲ 12766.6% | -272.07M▼ 191.9% | -5.3M▲ 98.1% | 1.36M▲ 125.7% | -5.71M▼ 518.7% | -897K▲ 0% |
Free Cash Flow | -139K▲ 0% | -8.74M▼ 6191.4% | -30.91M▼ 253.5% | -52.23M▼ 69.0% | -58.82M▼ 12.6% | -43.45M▲ 26.1% | -54.55M▼ 25.6% | -54.12M▲ 0% |
FCF Margin % | -16666.67% | - | - | - | - | - | - | - |
FCF Growth % | - | -6191.37% | -253.52% | -68.96% | -12.6% | 26.13% | -25.56% | -13.53% |
FCF per Share | -0.01 | -0.32 | -0.67 | -0.94 | -1.05 | -0.77 | -0.95 | -0.88 |
FCF Conversion (FCF/Net Income) | 0.07x | 1.05x | 0.83x | 0.81x | 0.88x | 0.87x | 0.78x | 0.78x |
Interest Paid | 0 | 24K | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DSGN Key Ratios
Design Therapeutics, Inc. (DSGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -19.16% | -17.85% | -22.1% | -19.08% | -30.7% | -33.07% |
Return on Invested Capital (ROIC) | - | -73.12% | -25.88% | -20.79% | -19.44% | -28.51% | -30.06% |
Debt / Equity | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x |
FCF Conversion | 1.05x | 0.83x | 0.81x | 0.88x | 0.87x | 0.78x | 0.78x |
Revenue Growth | -100% | - | - | - | - | - | - |
Related:DSGN Dividend History·DSGN Revenue History·DSGN Price History·DSGN P/E History·DSGN Financial Ratios·DSGN Institutional Holders
DSGN SEC Filings & Documents
Design Therapeutics, Inc. (DSGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
DSGN Frequently Asked Questions
Design Therapeutics, Inc. (DSGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Design Therapeutics, Inc. (DSGN) grew revenue by 0.0% over the past year. Growth has been modest.
Design Therapeutics, Inc. (DSGN) reported a net loss of $69.7M for fiscal year 2025.
Dividend & Returns
Design Therapeutics, Inc. (DSGN) has a return on equity (ROE) of -30.7%. Negative ROE indicates the company is unprofitable.
Design Therapeutics, Inc. (DSGN) had negative free cash flow of $54.1M in fiscal year 2025, likely due to heavy capital investments.